Scilex Holding Co
Scilex Holding Co (SCLX) is a small‑cap speciality pharmaceutical company (market capitalisation roughly $101.84M). It is best known for focusing on therapies in the pain management space and related niche indications, where progress hinges on clinical development, regulatory decisions and commercial execution. For investors, SCLX represents a higher‑risk, higher‑volatility opportunity: meaningful share‑price moves often follow trial readouts, FDA actions or partnership news. Financial health, cash runway and potential dilution are important considerations alongside the science. Because the company is smaller and less liquid than large caps, trading can be choppy and spreads wider. This summary is educational only and not investment advice; it’s important to review the company’s filings, investor presentations and independent research, and to consider your own risk tolerance and time horizon before making decisions. Past performance is not indicative of future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Scilex's stock as it may not significantly rise or fall soon.
Financial Health
Scilex Holding Co is performing well with solid revenue and profit margins, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SCLX
Executive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketBeyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory steps can be primary value drivers; timing of results often drives short‑term moves, though outcomes can vary.
Small‑cap Volatility
With a market cap near $102M, the stock can be more volatile and less liquid than larger peers, so position size and risk management matter.
Regulatory Watch
Approvals, label changes or partnerships influence commercial prospects; regulatory uncertainty is a standard risk in this sector.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
